NYSE: CVRS PRICE: 1.25 -0.04 -3.1% Volume: 416,462 20 minute delay. November 8, 2018

Press Releases

Corindus to Report Third Quarter Financial Results on November 6, 2018

October 30, 2018

WALTHAM, Mass.--(BUSINESS WIRE)-- Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it will release financial and business results for the third quarter of 2018 on Tuesday, November 6, 2018 after the close of the U.S. financial markets.

Mark Toland, President and Chief Executive Officer, and David Long, Chief Financial Officer, will host a conference call to discuss the results as follows:

    Date     Tuesday, November 6, 2018
Time 4:30 p.m. EST
Toll free (U.S.) (833) 286-5802
International (647) 689-4447
Conference ID: 8085557
Webcast (live and replay)

www.corindus.com under the ‘Investor Relations’ section.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and percutaneous vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

Trevi Communications
Media Contact:
Lisa Murray, 978-750-0333 ext. 2
lisa@trevicomm.com
or
In-Site Communications, Inc.
Investor Contact:
Lisa Wilson, 917-543-9932
ir@corindus.com

Source: Corindus Vascular Robotics, Inc.

Email Alerts

Mailing Lists *




Email Address *

 
Enter the code shown above.

Investor Contact

Scott Madden
508-653-3335 Ext 504
ir@corindus.com